Business Context and Reporting Period
Company: Therapix Biosciences Ltd. (Note: Request metadata listed "Scisparc Ltd.", but the filing identifies the registrant as Therapix Biosciences Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: March 28, 2019
Context: The Company announced the entry into a definitive securities purchase agreement for a registered direct offering and a concurrent private placement of warrants.
Key Financial Metrics
This filing is a current report regarding a capital raise and does not contain audited financial statements, revenue, profit, or cash flow data for a specific period.
| Metric | Value |
|---|---|
| Total Gross Proceeds (Expected) | Approximately $2.25 million |
| ADSs to be Issued (Registered Direct) | 642,853 ADSs (representing 25,714,120 ordinary shares) |
| Warrants Issued (Private Placement) | 482,139 Warrants (representing 19,285,560 ordinary shares) |
| Purchase Price per ADS | $3.50 |
| Warrant Exercise Price | $3.50 per ADS |
| Warrant Term | 3 years |
Material Changes
The filing details a material change in the Company's capital structure through the Offerings. The Company expects to raise approximately $2.25 million in gross proceeds. This transaction involves the issuance of new equity securities and warrants, which will increase the number of outstanding shares upon exercise.
Guidance, Outlook, and Risks
- Closing Date: The sale of ADSs and Warrants is expected to close on or about April 1, 2019, subject to customary closing conditions.
- Forward-Looking Statements: The report contains forward-looking statements regarding the expected closing. Actual results may differ materially due to risks and uncertainties.
- Contingencies: The Offerings are subject to various conditions and contingencies customary in securities purchase agreements. If conditions are not satisfied, the Offerings may not close.
- Regulatory Status: The Warrants and underlying ADSs are offered pursuant to Section 4(a)(2) of the Securities Act and Regulation D; they may not be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the actual closing date of the Offerings (expected April 1, 2019) and confirm if all closing conditions were satisfied.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific covenants and redemption terms.
- Confirm the final number of shares issued and the total net proceeds after deducting underwriting fees and offering expenses.
- Assess the dilution impact of the 642,853 new ADSs and the potential 482,139 warrant exercises on existing shareholders.
- Check subsequent filings for any updates regarding the use of proceeds or changes in the Company's financial position.